Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

Cell

Volumn 101, Issue 1, 2000, Pages 57-66

  Yamamoto, Ai ^a   Lucas, José J ^a   Hen, René ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DEGENERATIVE DISEASE; GENE CONTROL; GENE MUTATION; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPRESSOR GENE; TRANSGENE;

ANIMALIA;

EID: 0034737299     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)80623-6     Document Type: Article

References (53)

1. Ubiquitin, cellular inclusions and their role in neurodegeneration
2. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat
3. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease
4. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons
5. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes
6. Co-regulation of two gene activities by tetracycline via a bidirectional promoter
7. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
8. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
9. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
10. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease
11. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
12. From neuronal inclusions to neurodegeneration: Neuropathological investigation of a transgenic mouse model of Huntington's disease
13. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
14. Inactivation of the mouse Huntington's disease gene homolog Hdh
15. Use of tetracycline-controlled gene expression systems to study mammalian cell cycle
16. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter
17. Differential addressing of 5-HT1A and 5-HT1B receptors in epithelial cells and neurons
18. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
19. Trinucleotide instability: A repeating theme in human inherited disorders
20. Regional specificity of brain atrophy in Huntington's disease
21. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
22. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
23. Early loss of neostriatal striosome neurons in Huntington's disease
24. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
25. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells
26. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice
27. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
28. The CAG/polyglutamine tract diseases: Gene products and molecular pathogenesis
29. Structural neurology: Are seeds at the root of neuronal degeneration?
30. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease
31. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice
32. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice
33. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
34. Huntington's disease. Pathogenesis and management
35. Control of memory formation through regulated expression of a CaMKII transgene
36. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus
37. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes
38. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat
39. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
40. Reactive astrocytes: Cellular and molecular cues to biological function
41. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
42. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence
43. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
44. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
45. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
46. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study
47. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation
48. Huntington disease
49. Neuropathological classification of Huntington's disease
50. Homozygotes for Huntington's disease
51. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse
52. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
53. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue